10 Hottest Smid-Cap Stocks So Far In 2025

As the name suggests, smid-cap stocks have a valuation between $200 million and $20 billion. The definition is pretty flexible, but I’ll be working with the broadest one. Most stocks on the market fall into this category, so I think it is a good way to check the general pulse of the broader economy and look into some up-and-coming companies that may one day be the large caps of tomorrow.

We will be taking a look at some of them in this article by looking through stocks within the aforementioned market cap, sorted by their year-to-date gains so far in 2025. Do note that OTC stocks will not be included in this list.

You should keep in mind that while some of these stocks could be good buys, there is also a significant downside risk to stocks that have gained a lot recently. Regardless, let’s take a look at the top 10 stocks.

A close-up of a chart of company stock prices rising, reflecting its market capitalization.

10. Inari Medical (NASDAQ:NARI)

YTD Performance: 53.5%

Inari Medical (NASDAQ:NARI) makes medical devices. These devices are mostly used to treat blot clots in veins. Inari Medical is what I discussed before in an article talking about mid-cap stocks. Why is it surging so much this year? In short, Stryker announced it’s buying Inari Medical for $4.9 billion at $80 per share in cash.

Click here for more details.

9. Cerence (NASDAQ:CRNC)

YTD Performance: 61.16%

Cerence (NASDAQ:CRNC) is a tech company that makes voice-based virtual assistants for cars and other forms of transportation. It designs its AI software to handle natural language interactions so that drivers can speak naturally instead of tapping at screens or scrolling through menus. Most of Cerence’s revenue comes from licensing its in-car voice recognition technology and cloud-connected services to automakers worldwide. It has also expanded into generative AI for next-generation in-vehicle experiences, and this shift has drawn plenty of attention.

Cerence expects total revenue in a range of $236 million to $247 million, which includes about $20 million from fixed contracts. The company hit a negative adjusted EBITDA figure of $1.9 million in the fourth quarter of fiscal 2024, yet it exceeded revenue expectations in that same quarter by posting $54.8 million. Its management team has stated that profitability in 2025 is a top priority, and it has outlined cost savings of $35 million to $40 million. Analysts covering Cerence are slightly more optimistic now than they were several months ago, and they see a revenue potential of roughly $242 million in 2025.

Cerence then announced a shift to generative AI in November. This is mainly what caused the spike that month last year. It then repurchased $27 million of its convertible senior notes due 2025 at a discount in December and expanded partnerships with Nvidia (NASDAQ:NVDA). These back-to-back events are why CRNC turned into a multibagger.

It is now well over $13.